Formulation of Inhalation Medicines

Inhalation Drug Delivery: Techniques and Products

Volumn , Issue , 2013, Pages 31-45

  Traini, Daniela ^a   Young, Paul M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Carriers, and ordered mixing; Device with powder formulation; DPI formulation; DPIs, carrier based agglomerated; HFAs, potential alternative; Inhalation medicines, formulation; PMDI formulation; PMDI, suspension technology; PMDI DPI, improved lung deposition; Solution based pMDIs

Indexed keywords

DPI FORMULATION; DPIS, CARRIER-BASED/AGGLOMERATED; HFAS, POTENTIAL ALTERNATIVE; INHALATION MEDICINES, FORMULATION; LUNG DEPOSITIONS; PMDI FORMULATION; POWDER FORMULATIONS;

EID: 84886224607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118397145.ch3     Document Type: Chapter

References (36)

1. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes-chlorine atomic-catalysed destruction of ozone Nature 1974;249(5460):810-812.
2. Jones DS, McCoy CP. Heptafluoropropane (HFC). In Rowe RC, Sheskey PJ,Weller PJ, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2009. pp. 303-305.
3. Alexander DJ, Libretto SE. An overview of the toxicology of Hfa-134a (1,1,1,2- tetrafluoroethane) Human & Experimental Toxicology 1995;14(9):715-720.
4. Solvay Fluor. Solka ne 1 227 Pharma and 13 4a Ph arma Data Sheet. http:// www.solvaychemicals.com/EN/products/Fluor/Hydrofluorocarbons_HFC/ Solkane227pharma.aspx and http://www.solvaychemicals.com/EN/products/Fluor/ Hydrofluorocarbo ns_HFC/Solkane1 34aph ar ma. aspx. 2010 [last accessed Jan 17, 2010].
5. Smyth HDC. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers Advanced Drug Delivery Reviews 2003;55(7):807-828.
6. Atkins PJ, editor. The Development of New Solution Metered Dose Inhaler Delivery Systems. Buffalo Grove, IL: Proceedings of Respiratory Drug Delivery; 1990.
7. Kontny MJ, Destefano G, Jager PD, Mcnamara DP, Turi JS, Vancampen L. Issues surrounding MDI formulation development with non-CFC propellants Journal of Aerosol Medicine 1991;4(3):181-187.
8. Traini D, Young PM, Rogueda P, Price R. Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers International Journal of Pharmaceutics 2006;320(1-2):58-63.
9. Ashurst ICW (GB), Herman CSR (NC), Li LSP (NJ), Riebe MTR (NC), inventors; Glaxo Wellcome Inc. (Research Triangle Park, NC); Glaxo Group Limited (Greenford, GB), assignee. Metered dose inhaler for salmeterol. US patent 6143277. 1996.
10. Leach CL. Targeting inhaled steroids International Journal of Clinical Practice 1998;96:23-27.
11. Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T. Modulite (R):a means of designing the aerosols generated by pressurized metered dose inhalers Respiratory Medicine 2002;96:S3-S8.
12. Hersey JA. Ordered mixing-new concept in powder mixing practice 17 Powder Technology 1975;11(1):41-44.
13. Hinds WC. Aerosol Technology. New York, NY: John Willey & Sons, Ltd; 1999.
14. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today Pulmonary Pharmacology & Therapeutics 2003;16(2):79-95.
15. Edge S, Kaerger S, Shur J. Lactose, inhalation. In Rowe RC, Sheskey PJ,Weller PJ, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2009. pp. 362-4.
16. Edge S, Kaerger S, Shur J. Lactose, anhydrous. In Rowe RC, Sheskey PJ,Weller PJ, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2009. pp. 359-361.
17. Edge S, Kaerger S, Shur J. Lactose, monohydrate. In Rowe RC, Sheskey PJ,Weller PJ, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2009. pp. 364-369.
18. Edge S, Kaerger S, Shur J. Lactose, spray-dried. In Rowe RC, Sheskey PJ, Weller PJ, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2009. pp. 376-378.
19. Kaerger SJ, Price R, Young PM, Tobyn MJ. Carriers for DPIs: formulation and regulatory challenges. Pharmaceutical Technology Europe 2006; October edition:25-30.
20. Young PM, Edge S, Traini D, Jones MD, Price R, El-Sabawi D, et al. The influence of dose on the performance of dry powder inhalation systems 1 International Journal of Pharmaceutics 2005;296(1-2):26-33.
21. El-Sabawi D, Edge S, Price R, Young P. Continued investigation into the influence of loaded dose on the performance of dry powder inhalers: surface smoothing effects Drug Development and Industrial Pharmacy 2006;32(10):1135-1138.
22. Islam N, Stewart P, Larson I, Hartley P. Lactose surface modification by decantation:are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures? 2 Pharmaceutical Research 2004;21(3):492-499.
23. Jones MD, Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations Pharmaceutical Research 2006;23(8):1665-1674.
24. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers:fine particle multiplets as performance modifiers Pharmaceutical Research 1998;15(4):562-569.
25. Young PM, Traini D, Chan HK, Chiou H, Edge S, Tee T. The influence of mechanical processing dry powder inhaler carriers on drug aerosolisation performance Journal of Pharmaceutical Sciences 2007;96(5):1331-1341.
26. Ferrari F, Cocconi D, Bettini R, Giordano F, Sant P, Tobyn MJ et al. The surface roughness of lactose particles can be modulated by wet-smoothing using a highshear mixer AAPS PharmSciTech 2004;5(4):1-6.
27. El-Sabawi D, Price R, Edge S, Young PM. Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations 1 Drug Development and Industrial Pharmacy 2006;32(2):243-251.
28. Zeng XM, Martin GP, Marriott C, Pritchard J. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate European Journal of Pharmaceutics and Biopharmaceutics 2001;51(1):55-62.
29. Young PM, Roberts D, Chiou H, Rae W, Chan HK, Traini D. Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery Journal of Aerosol Science 2008;39(1):82-93.
30. Tee SK, Marriott C, Zeng XM, Martin GP. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate International Journal of Pharmaceutics 2000;208(1-2):111-123.
31. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations International Journal of Pharmaceutics 2004;270(1-2):297-306.
32. Traini D, Young PM, Jones MD, Edge S, Price R. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation European Journal of Pharmaceutical Sciences 2006;27(2-3):243-251.
33. Traini D, Young PM, Thielmann F, Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations Drug Development and Industrial Pharmacy 2008;34(9):992-1001.
34. Kumon M, Suzuki M, Kusai A, Yonemochi E, Terada K. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC Chemical & Pharmaceutical Bulletin 2006;54(11):1508-1514.
35. Chies i. Beclo metasone Pulvi nal Produc t Data Sheet. http:// www.medicine s.org.uk/ EMC/medicine/21030/SPC/Pulvinal%20Beclometasone%20Inhaler%20100,200% 20and%20400%20micrograms/.
36. Wetterlin K. Turbuhaler-a new powder inhaler for administration of drugs to the airways. Pharmaceutical Research 1988;5(8):506-508.